Loading...
Please wait, while we are loading the content...
Renal Impairment: Elimination of THYROGEN is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels. (8.6) See 17 for PATIENT COUNSELING INFORMATION Revised: [3/2014] FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
| Content Provider | Semantic Scholar |
|---|---|
| Copyright Year | 2014 |
| Abstract | ----------------------------INDICATIONS AND USAGE--------------------------THYROGEN® is a thyroid stimulating hormone indicated for: Diagnostic: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. (1.1) Limitations of Use: THYROGEN-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal. Even when THYROGEN-Tg testing is performed in combination with radioiodine imaging , there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease. Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable. |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020898s060lbl.pdf |
| Alternate Webpage(s) | https://www.thyrogen.com/~/media/Thyrogen/Files/PDFs/pi.ashx |
| Alternate Webpage(s) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020898s054lbl.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |